Received: 19 January 2022
Accepted: 15 June 2022
First Online: 23 June 2022
: The samples used in this study belong to the MASH study, which was supported by Rigshospitalet and a study grant from the Danish Rheumatism Association (R102-A2132-B98).
: Not applicable
: Dr. Nielsen is full-time employee at Nordic Bioscience A/S. Dr. Bay-Jensen and Dr. Karsdal are employed at and own stocks in Nordic Bioscience A/S. Dr. Seven has received consulting fees, speaking fees, and/or honoraria from UCB and Sanofi (less than $10,000 each) and from Novartis (more than $10,000) and research support from Novartis. Dr. Østergaard has received consulting fees, speaking fees, and/or honoraria from AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Celegene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB (less than $10,000 each). Dr. Pedersen has received speaking fees from MSD, Pfizer, AbbVie, and UCB (less than $10,000 each), consulting fees and/or honoraria from AbbVie (less than $10,000), consulting fees, speaking fees, and/or honoraria from Novartis (more than $10,000), and research support from AbbVie, MSD, and Novartis.